Global and China Receptor Tyrosine Protein Kinase ERBB 3 Market Research by Company, Type & Application 2013-2025

Table of Content

1 Market Overview

• 1.1 Market Segment Overview
  • 1.1.1 Product Definition
  • 1.1.2 Market by Type
    • 1.1.2.1 BA-0702
    • 1.1.2.2 CDX-3379
    • 1.1.2.3 Elgemtumab
    • 1.1.2.4 ETBX-031
    • 1.1.2.5 Others
  • 1.1.3 Market by Application
    • 1.1.3.1 Non-Small Cell Carcinoma
    • 1.1.3.2 Solid Tumor
    • 1.1.3.3 Melanoma
    • 1.1.3.4 Colorectal Cancer
    • 1.1.3.5 Others
• 1.2 Global and China Market Size
  • 1.2.1 Global Overview
  • 1.2.2 China Overview

2 Global and China Market by Company

• 2.1 Global
  • 2.1.1 Global Sales by Company
  • 2.1.2 Global Price by Company
• 2.2 China
  • 2.2.1 China Sales by Company
  • 2.2.2 China Price by Company

3 Global and China Market by Type

• 3.1 Global
  • 3.1.1 Global Sales by Type
  • 3.1.2 Global Price by Type
• 3.2 China
  • 3.2.1 China Sales by Type
  • 3.2.2 China Price by Type

4 Global and China Market by Application

• 4.1 Global
  • 4.1.1 Global Sales by Application
  • 4.1.2 Global Price by Application
• 4.2 China
  • 4.2.1 China Sales by Application
  • 4.2.2 China Price by Application

5 China Trade

• 5.1 Export
• 5.2 Import

6 Key Manufacturers

• 6.1 AstraZeneca Plc
  • 6.1.1 Company Information
  • 6.1.2 Product Specifications
  • 6.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 6.2 AVEO Pharmaceuticals, Inc.
• 6.3 Etubics Corporation
• 6.4 F. Hoffmann-La Roche Ltd.
• 6.5 GamaMabs Pharma S.A.
• 6.6 GlaxoSmithKline Plc
• 6.7 Hanmi Pharmaceuticals, Co. Ltd.
• 6.8 ImmunoGen, Inc.
• 6.9 Kolltan Pharmaceuticals, Inc.
• 6.10 Merrimack Pharmaceuticals, Inc.
• 6.11 Merus B.V.
• 6.12 Novartis AG
• 6.13 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
• 6.14 Sihuan Pharmaceutical Holdings Group Ltd.
• 6.15 Sorrento Therapeutics, Inc.
• 6.16 Symphogen A/S
• 6.17 Takis S.r.l.

7 Industry Upstream

• 7.1 Industry Chain
• 7.2 Raw Materials

8 Market Environment

• 8.1 SWOT
• 8.2 Porter's Five Forces

9 Conclusion